Our previous work identified the inhibition of glutaminase as a metabolism-based strategy to combine with CDK4/6 targeting therapy [36], a combination subsequently corroborated as effective to overcome CDK4/6i resistance in esophageal squamous cell carcinoma [92] and lung cancer [93]. This evidence concerns the gene CDK4 and lung cancer.